GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

Blood

Volumn 115, Issue 19, 2010, Pages 3939-3948

  Streetly, Matthew J ^a,b   Maharaj, Lenushka ^b   Joel, Simon ^b   Schey, Steve A ^c   Gribben, John G ^b   Cotter, Finbarr E ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D2; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYCLIN E2; GALECTIN 3; GCS 100; I KAPPA B ALPHA; I KAPPA B KINASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CASPASE; GCS-100; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PMAIP1 PROTEIN, HUMAN; POLYSACCHARIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION; COCULTURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; PATHOLOGY; STROMA CELL; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL PROLIFERATION; COCULTURE TECHNIQUES; ENZYME ACTIVATION; GALECTIN 3; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIPLE MYELOMA; POLYSACCHARIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 77952989057     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-251660     Document Type: Article

References (43)

1. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005;18(4):619-634. (Pubitemid 40984118)
2. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006;132(4):385-397. (Pubitemid 43381614)
3. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis. 2003;8(4):337-343. (Pubitemid 36935205)
4. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005;18(4):509-524.
5. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115. (Pubitemid 29077388)
6. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29(12):3945-3950.
7. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x (L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194-199. (Pubitemid 35177447)
8. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885-1893. (Pubitemid 34525465)
9. Chen-Kiang S. Biology of plasma cells. Best Pract Res Clin Haematol. 2005;18(4):493-507.
10. Hyun T, YamA, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood. 2000;96(10):3560-3568.
11. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and up-regulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21(37):5673-5683. (Pubitemid 35333000)
12. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60(23):6763-6770.
13. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2000;96(8):2856-2861.
14. Lentzsch S, Chatterjee M, Gries M, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia. 2004;18(11):1883-1890. (Pubitemid 39530020)
15. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21(43):6587-6597. (Pubitemid 35177037)
16. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20(42):5991-6000. (Pubitemid 32955041)
17. Hsu JH, Shi Y, Hu L, et al. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene. 2002;21(9):1391-1400. (Pubitemid 34214504)
18. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639-16647. (Pubitemid 34967682)
19. Tai YT, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003;101(7):2762-2769. (Pubitemid 36857641)
20. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635.
21. Hoyer KK, Pang M, Gui D, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004;164(3):893-902. (Pubitemid 38235471)
22. Nakahara S, Oka N, Wang Y, et al. Characterization of the nuclear import pathways of galectin-3. Cancer Res. 2006;66(20):9995-10006. (Pubitemid 44672052)
23. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis. 2005;10(2):267-275.
24. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A. 1996;93(13):6737-6742. (Pubitemid 26230379)
25. Hanada M, Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein: identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem. 1995;270(20):11962-11969.
26. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57(23):5272-5276. (Pubitemid 27516362)
27. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005;65(18):8350-8358. (Pubitemid 41330600)
28. Inohara H, Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J. 1994;11(6):527-532.
29. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87(5):348-353.
30. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94(24):1854-1862. (Pubitemid 36104630)
31. Springate CF, Cartwright T, Belt R, Redfern C, Stuart K. Phase II study of GBC-590 in patients with relapsing or refractory colorectal cancer. Am Soc Clin Oncol. 2001;20:2226a.
32. Cotter F, Smith DA, Boyd TE, et al. Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. J Clin Oncol (Meeting Abstracts). 2009;27(15)[suppl]:7006.
33. Cotter FE, Gribben J, Streetly M, et al. Clinical caspase activation in CLL by GCS-100, a novel carbohydrate, in a phase 2 study. Ann Oncol. 2008;1990(suppl 4):iv.
34. Jüliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-κB inhibition and the rapid generation of other selenium species. Cancer Res. 2007;67(22):10984-10992. (Pubitemid 350145928)
35. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med. 1996;184(3):1155-1160. (Pubitemid 26313572)
36. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181(5):1661-1672.
37. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20(33):4519-4527. (Pubitemid 32772434)
38. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67(11):5418-5424. (Pubitemid 46997282)
39. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene. 2008;27(6):721-731. (Pubitemid 351186317)
40. Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001;98(7):2183-2192.
41. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood. 2006;108(4):1346-1352. (Pubitemid 44232035)
42. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem. 2006;281(15):10153-10163. (Pubitemid 43864551)
43. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076. (Pubitemid 32691956)